Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that it will participate in the following investor conferences in March 2025:

TD Cowen 45th Annual Health Care Conference Conference Dates: March 3-5, 2025 Presentation Date/Time: March 4, 2025, 1:10 p.m. ET

Leerink Partners Global Healthcare Conference 2025 Conference Dates: March 10-12, 2025 Presentation Date/Time: March 10, 2025, 1:40 p.m. ET

Live webcast links for both presentations will be available on the events tab of Immunome’s investor website. Replay links of the presentations will also be available on the website for 30 days following the live broadcast.

About Immunome

Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted therapies designed to improve outcomes for cancer patients. We are advancing an innovative portfolio of therapeutics, drawing on leadership that previously played key roles in the design, development, and commercialization of cutting-edge targeted cancer therapies, including antibody-drug conjugate therapies (ADCs). Our most advanced pipeline programs are varegacestat (formerly AL102), a gamma secretase inhibitor which is currently in a Phase 3 trial for treatment of desmoid tumors, IM-1021, a ROR1 ADC with an active IND, and IM-3050, a FAP-targeted radioligand, which is the subject of an IND expected to be submitted in the first quarter of 2025. Our pipeline also includes IM-1617, IM-1335, and IM-1340, all of which are preclinical ADCs pursuing undisclosed targets with expression in multiple solid tumors. For more information, visit www.immunome.com.

Cautionary Statement Regarding Forward-Looking Statements

Statements in this press release that are not purely historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include Immunome’s expectations regarding progress of its pipeline and timeline for regulatory filings, and other statements regarding forecasts for the future. These forward-looking statements are based on Immunome’s current expectations and involve assumptions that may never materialize or may prove to be incorrect; consequently, actual results may differ materially from those expressed or implied in the statements due to a number of factors, including, but not limited to, the risks and uncertainties described in Immunome’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, filed with the SEC on November 13, 2024, and in Immunome’s other filings with the SEC. Except as required by law, Immunome assumes no obligation and does not intend to update any forward-looking statements included in this press release.

Investor Contact Max Rosett Chief Financial Officer investors@immunome.com

Immunome (NASDAQ:IMNM)
Historical Stock Chart
From Feb 2025 to Mar 2025 Click Here for more Immunome Charts.
Immunome (NASDAQ:IMNM)
Historical Stock Chart
From Mar 2024 to Mar 2025 Click Here for more Immunome Charts.